Business & Industry
AstraZeneca’s Baxfendy Wins FDA Approval for Uncontrolled Hypertension
AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received approval from the U.S. Food and Drug Administration, opening a new treatment pathway for millions of patients whose high blood pressure remains uncontrolled despite existing therapies. The Anglo-Swedish pharmaceutical company...
Business & Industry
EU Advances Critical Medicines Act to Cut Import Reliance
The European Union has moved closer to implementing new measures aimed at protecting the availability of essential medicines and reducing exposure to external supply risks, as lawmakers advanced the Critical Medicines Act framework first introduced in March 2025. The...
Business & Industry
Novartis Expands Radioligand Therapy Manufacturing in US
Swiss pharmaceutical company Novartis has started construction of a new manufacturing facility in Denton, Texas, as part of its previously announced $23 billion investment plan aimed at expanding research and production operations across the United States. The project, expected...
Business & Industry
Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition
Angelini Pharma has finalized a definitive agreement to acquire Catalyst Pharmaceuticals for an equity value of approximately €3.5bn ($4.1bn). This move marks a strategic entry into the US market for the company, further consolidating its operational focus on brain...
News
Are Glutathione Injections in NYC Worth It? A Complete Guide
When whatever you do to your skin makes it look dull, uneven, or tired, you are not alone. Many people in New York look for easy wellness solutions that could achieve a healthier and brighter look on the inside....
Drug Research
Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform
FUJIFILM Corporation has developed a new screening methodology aimed at identifying cyclic peptides with high affinity toward membrane proteins, including complex multi-pass transmembrane proteins that have traditionally been difficult to target in drug discovery research. The company announced that...
Business & Industry
UCB Acquires Candid Therapeutics in a $2 Billion-Plus Deal to Strengthen Immunology Pipeline
Belgian pharmaceutical company UCB is making a substantial move to expand its immunology pipeline, entering into a multi-billion dollar agreement to acquire Candid Therapeutics a clinical-stage biotechnology company working on therapies designed to treat autoimmune disorders by resetting the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read